4,5-dihydroquinolizin-5-ium-1-olate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹嗪类
• 英文名称: 4,5-dihydroquinolizin-5-ium-1-olate
• 化学式: C₉H₉NO
• mdl: MFCD01859755
• 分子量: 147.17
• InChiKey: PPACKVQYUBEMGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Novel physiologically active substances
  申请人：Kotake Yoshihiko

  公开号：US20050245514A1

  公开（公告）日：2005-11-03

  Compounds represented by the following general formula (I), pharmacologically acceptable salts thereof or hydrates of the same: (I) wherein W represents and R 3 , R 7 , R 16 , R 17 , R 20 , R 21 and R 21′ are the same or different and each represents hydrogen, etc. Because of inhibiting angiogenesis and inhibiting the production of VEGF particularly in hypoxia, the compounds (I) are useful as remedies for solid cancer.

  具有下述通式(I)表示的化合物、其药理学上可接受的盐或水合物：(I)其中W代表，R3、R7、R16、R17、R20、R21及R21'相同或不同，各自代表氢等。由于能抑制血管生成及在缺氧条件下抑制VEGF的产生，化合物(I)可作为实体癌症的治疗药物。
• Heterocyclic compound having oxime group
  申请人：Yoshida Ichiro

  公开号：US20050227959A1

  公开（公告）日：2005-10-13

  The present invention provides a compound that has an excellent inhibitory activity on STAT6 activation and is effective against allergic diseases, and a medicinal composition thereof. According to the present invention, disclosed is the compound represented by the General Formula (I) [where R 1 and R 2 independently represent a C 1-6 alkyl group and the like that may have a hydrogen atom or a substituent; R 3 represents a C 1-6 alkyl group and the like that may have a substituent; R 4 and R 5 independent represents a hydrogen atom or a C 1-6 alkyl group and the like that may have a substituent; R 6 represents a hydrogen atom and the like; W represents —SO 2 — and the like; and X represents a sulphur atom and the like.]or a salt thereof, or a hydrate thereof.

  本发明提供了一种对STAT6激活具有优异抑制活性且对过敏疾病有效的化合物及其药物组合物。根据本发明，公开了由通式（I）表示的化合物[其中R1和R2独立地表示可能具有氢原子或取代基等的C1-6烷基基团；R3表示可能具有取代基的C1-6烷基基团等；R4和R5独立地表示可能具有取代基的氢原子或C1-6烷基基团等；R6表示氢原子等；W表示—SO2—等；X表示硫原子等]或其盐或水合物。
• Method for Producing Aromatic and Heteroaromatic Carboxylic Acids, Carboxylic Acid Esters and Carboxylic Acid Amides
  申请人：Challand Nina

  公开号：US20110172456A1

  公开（公告）日：2011-07-14

  Process for the preparation of aromatic and heteroaromatic carboxylic acids, carboxylic acid esters and carboxamides by the reaction of aromatic or heteroaromatic halides R—X n , in which n=integer from 1 to 6, R=substituted or unsubstituted and aromatic or heteroaromatic radical and X=chlorine, bromine or iodine atom, with carbon monoxide and water, ammonia, alcohols or amines in the presence of bases and zero-valent or divalent palladium compounds and bidentate diphosphanes or complexes of zero-valent or divalent palladium with bidentate diphosphanes, in which use is made of bidentate diphosphanes (R 1 —)(R 2 —)P—Y—P(—R 3 )(—R 4 ) in which R 1 to R 4 =unsubstituted aryl radicals or aryl radicals substituted with at least one radical exhibiting a positive resonance effect or a positive inductive effect, or unsubstituted or substituted cycloalkyl radicals, and Y=hydrocarbon group with a total of 2 to 20 carbon atoms, in which at least one of the carbon atoms carries only one or no hydrogen atom as substituent; except for the reaction of 4-bromo-3-difluoromethyl-1-methylpyrazole with 2-(3,4,5-trifluorophenyl)aniline and carbon monoxide to give N-[2-(3,4,5-trifluorophenyl)phenyl]-3-difluoromethyl-1-methylpyrazole-4-carboxamide.

  用芳香或杂芳卤代烃R—Xn（其中n=1到6的整数，R=取代或未取代的芳香或杂芳基团，X=氯、溴或碘原子）与一氧化碳和水、氨、醇或胺在碱存在下，以及零价或二价钯化合物和双膦或零价或二价钯与双膦的配合物反应，制备芳香和杂芳羧酸、羧酸酯和羧酰胺的方法的过程，其中使用双膦(R1—)(R2—)P—Y—P(—R3)(—R4)，其中R1到R4=未取代芳基基团或带有至少一个正共振效应或正归纳效应的基团的取代芳基基团，或未取代或取代的环烷基基团，Y=含有2到20个碳原子的碳氢基团，其中至少一个碳原子只携带一个或没有氢原子作为取代基；但不包括4-溴-3-二氟甲基-1-甲基吡唑与2-(3,4,5-三氟苯基)苯胺和一氧化碳反应形成N-[2-(3,4,5-三氟苯基)苯基]-3-二氟甲基-1-甲基吡唑-4-羧酰胺。
• Novel physiologically active substance
  申请人：Nagai Mitsuo

  公开号：US20060235002A1

  公开（公告）日：2006-10-19

  A compound represented by the following general formula (I): (I) wherein R 7 and R 21 are the same or different and each represents optionally substituted C 2-22 alkoxy, etc.; a pharmaceutically acceptable salt thereof or hydrates of the same. The compound (1) inhibits angiogenesis and inhibits the production of VEGF particularly under hypoxic conditions, which makes it useful as a remedy for solid cancer.

  以下是一种由下列通式（I）表示的化合物：（I）其中，R7和R21相同或不同，每个都表示可选择取代的C2-22烷氧基等；其药学上可接受的盐或水合物。该化合物（1）抑制血管生成并抑制VEGF的产生，特别是在缺氧条件下，因此可用作固体癌症的治疗药物。
• NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES
  申请人：KOTAKE Yoshihiko

  公开号：US20080255146A1

  公开（公告）日：2008-10-16

  The present invention relates to a compound represented by the formula (I): (wherein, R 3 , R 6 , R 7 and R 21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.

  本发明涉及一种由式(I)表示的化合物：（其中，R3、R6、R7和R21相同或不同，每个代表羟基等），其药学上可接受的盐或水合物。本发明的化合物(I)抑制血管生成，特别是在低氧条件下抑制VEGF的产生，并且可用作治疗实体癌的治疗剂。